Lupus & antiphospholipid syndrome

Development of a least absolute shrinkage and selection operator (LASSO)-based machine learning model for relapse prediction in lupus nephritis

Lupus Sci MedPublished Cohort study

Authors' conclusion

Higher level of 24-hour proteinuria, higher SLEDAI-2K score and low complement C3 level were risk factors for LN relapse, while remission within 12 months was a protective factor. The LASSO-Cox-based predictive model exhibited good performance and may serve as a useful tool for the clinical management of LN.

Study context

Population
Patients with lupus nephritis (LN) who received renal biopsies from 2005 to 2024 in Xijing Hospital
Participants
831 patients
Exposure
Relapse vs no relapse
  • Relapsen = 225
Outcome
Renal relapse; performance of the relapse risk prediction model
Methodological detailsprediction model development, single-centre, LASSO-Cox variable selection, multivariate Cox regression, bootstrap resampling, landmark analysis at 12 months
  • Prediction model development
  • Single-centre
  • LASSO-Cox variable selection
  • Multivariate Cox regression
  • Bootstrap resampling
  • Landmark analysis at 12 months

Main finding

As reported in the abstract

Relapse prediction model performance · 12 months postbiopsy (model application)

Relapse

225/831 patients

27.08%

Bootstrap-corrected C-index

0.75

95% CI 0.72 to 0.79

Observational data: associations, not effects.

Further findings

Age of onset

P = 0.001

Proteinuria

P = 0.001

OutcomeRelapseNon-relapseP value
SLEDAI12.07.0P = 0.001

Nephritis histology

No significant difference between the two groups

IV methylprednisolone pulse therapy or belimumab

Proportion significantly higher in the non-relapse group

Original publication

Development of a LASSO-based machine learning model for relapse prediction in lupus nephritis. Lupus Sci Med. Published 25 June 2026. doi:10.1136/lupus-2026-002003

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.